Potential for linezolid-related blindness: A review of spontaneous adverse event reports

Pharmacotherapy

Volumn 31, Issue 6, 2011, Pages 585-590

  Brown, Jack ^a,b   Aitken, Samuel L ^a,c   Van Manen, Robbert P ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BUFFALO GENERAL HOSPITAL   (United States)

^d Lincoln Safety Group   (United States)

Author keywords

Adverse events; Blindness; Disproportionality analysis; Linezolid; Spontaneous reporting

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; VANCOMYCIN;

ABSCESS; ADULT; AGED; ARTICLE; BACTEREMIA; BLINDNESS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATION; DIABETIC FOOT; DISEASE ASSOCIATION; DISPROPORTIONALITY ANALYSIS; DRUG APPROVAL; DRUG EXPOSURE; DRUG SAFETY; ENTEROCOCCAL INFECTION; FEMALE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; GUILLAIN BARRE SYNDROME; HIGH RISK POPULATION; HUMAN; MALE; MYCOBACTERIOSIS; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RETROSPECTIVE STUDY; SEPSIS; STAPHYLOCOCCUS INFECTION; STATISTICAL ANALYSIS; TREATMENT DURATION; URINARY TRACT INFECTION; WOUND INFECTION;

ACETAMIDES; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BAYES THEOREM; BLINDNESS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; OPTIC NERVE DISEASES; OXAZOLIDINONES; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79957592476     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.6.585     Document Type: Article

References (22)

1. Bhavnani SM, Ballow CH. New agents for gram-positive bacteria. Curr Opin Microbiol 2000;3:528-34.
2. Pfizer, Inc. Zyvox (linezolid) package Insert. Groton, CT; 2008.
3. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129-40. (Pubitemid 37357649)
4. Vercillo M, Patzakis MJ, Holtom P, Zalavras CG. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007;461:40-3. (Pubitemid 47344092)
5. van Manen RP, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf 2007;6:451-64. (Pubitemid 351308174)
6. Javaheri M, Khurana RN, O'Hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007;91:111-15.
7. Kulkarni K, Del Priore LV. Linezolid-induced toxic optic neuropathy. Br J Ophthalmol 2005;89:1664-5.
8. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27:1189-97. (Pubitemid 47173662)
9. Azamfirei L, Copotoiu SM, Branzaniuc K, Szederjesi J, Copotoiu R, Berteanu C. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf 2007;16:402-4. (Pubitemid 46656861)
10. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the U.S. FDA's spontaneous reports database. Drug Saf 2002;25:381-92. (Pubitemid 34729136)
11. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med 2009;360:1113-24.
12. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001;61:525-51. (Pubitemid 32368068)
13. Wiener M, Guo Y, Patel G, Fries BC. Lactic acidosis after treatment with linezolid. Infection 2007;35:278-81. (Pubitemid 47222283)
14. Boutoille D, Grossi O, Depatureaux A, Tattevin P. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis. Eur J Intern Med 2009;20:e134-5.
15. Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009;28:149-51.
16. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005;40:e113-16.
17. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006;50:2042-9. (Pubitemid 43807524)
18. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005;353:2305-6.
19. Prydal JI, Jenkins DR, Lovering A, Watts A. The pharmacokinetics of linezolid in the non-inflamed human eye. Br J Ophthalmol 2005;89:1418-19. (Pubitemid 41527372)
20. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004;13:519-23. (Pubitemid 39214028)
21. Waller P, van Puijenbroek E, Egberts A, Evans S. The reporting odds ratio versus the proportional reporting ratio: 'deuce'. Pharmacoepidemiol Drug Saf 2004;13:525-8.
22. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003;12:559-74. (Pubitemid 37220642)